- Lonza Walkersville is investing in an expansion of its endotoxin assay production facility
- The upgraded facility will incorporate sustainable technologies and streamline manufacturing processes
- Endotoxin assays are used to help ensure the safety and compliance of parenteral drugs and medical devices
Walkersville, MD, 26 September 2024 – Lonza, a global partner to the pharmaceutical, biotech, and nutraceutical markets, today celebrated the start of construction for the expansion of its endotoxin assay production facility in Walkersville, MD (US). Lonza is renovating approximately 18,000 square feet of dedicated manufacturing space at the site to meet growing demand for endotoxin assay products.
Lonza Walkersville manufactures the materials required to execute the endotoxin assay, which is used by pharmaceutical companies, to assess endotoxin levels in all injectable pharmaceutical products and medical devices, to help ensure their safety and compliance with regulatory standards.
The investment in the facility supports Lonza's continued drive for operational excellence. By integrating state-of-the-art automation and cutting-edge facility enhancements, the upgraded space will be tailored specifically to Lonza’s endotoxin assay product portfolio.
As part of Lonza’s continued commitment to sustainability, the renovation will incorporate environmentally friendly technologies including energy-efficient systems, waste reduction initiatives, and responsibly sourced materials, to minimize environmental impact while boosting productivity. The project will address current regulatory and market needs while anticipating future technological advancements and industry growth.
Orla Cloak, Senior Vice President, Head of Bioscience, Lonza commented: “The investment in an advanced endotoxin manufacturing facility underscores our commitment to advancing biopharmaceutical innovation while helping to ensurethe highest standards of safety and quality. Once operational, the facility will enhance our capability and capacity to meet the growing demands of the injectable drugs market, providing our customers with reliable and high-quality products that are critical for patient safety.”
In attendance at the celebration were members of the Frederick County and Maryland governments, including Frederick County Executive, Jessica Fitzwater, who added: "Lonza’s investment in their Walkersville facility is an exciting development for Frederick County, demonstrating our region’s ability to attract and support cutting-edge biotech and manufacturing projects."
Additional Information
To learn more about Lonza’s Bioscience offering, please see here: Lonza Bioscience | Lonza